First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
暂无分享,去创建一个
Yun Yen | Glen J. Weiss | Mark E. Davis | Vincent Chung | C. H. J. Choi | Y. Yen | G. Weiss | D. Bassett | J. Ryan | T. Schluep | S. Forman | W. Chow | J. Longmate | T. Synold | J. Chao | Joseph Chao | Robert Morgan | Jungyeon Hwang | Jeffrey D. Neidhart | Ramesh K. Ramanathan | Dawn Bassett | James A. Neidhart | Chung Hang J. Choi | Warren Chow | Stephen J. Forman | Edward Garmey | D. Lynn Kalinoski | Marianna Koczywas | Jeffrey Longmate | Roger J. Melton | Jamie Oliver | Joanna J. Peterkin | John L. Ryan | Thomas Schluep | Timothy W. Synold | Przemyslaw Twardowski | R. Morgan | P. Twardowski | R. Ramanathan | J. Neidhart | M. Koczywas | Jungyeon Hwang | V. Chung | E. Garmey | J. Peterkin | J. Neidhart | J. Oliver | D. Kalinoski | R. Melton | Stephen J. Forman | Glen J. Weiss | James A. Neidhart | Chung Hang J. Choi | D. Lynn Kalinoski | Roger J. Melton | Joanna J. Peterkin | John L. Ryan | Mark E. Davis
[1] Yun Yen,et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. , 2012, Nanomedicine : nanotechnology, biology, and medicine.
[2] Jianjun Cheng,et al. Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice , 2006, Cancer Chemotherapy and Pharmacology.
[3] Sonke Svenson,et al. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[4] Mark E. Davis,et al. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. , 2009, Advanced drug delivery reviews.
[5] Yves Pommier,et al. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. , 2004, Current medicinal chemistry. Anti-cancer agents.
[6] C. Boland,et al. Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 status , 2002, International journal of cancer.
[7] Jianjun Cheng,et al. Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates , 2004 .
[8] Jae Cheol Lee,et al. HIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines , 2009, Journal of Cancer Research and Clinical Oncology.
[9] Mark E. Davis,et al. Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models , 2009, Clinical Cancer Research.
[10] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[11] Thomas J. Smith,et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Runowicz,et al. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Muggia Fm,et al. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. , 1972 .
[14] S. Steinberg,et al. Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors , 2011, Clinical Cancer Research.
[15] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[16] F. Bertucci,et al. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. , 2008, Cancer research.
[17] Mark E. Davis,et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements , 2009, Proceedings of the National Academy of Sciences.
[18] Jianjun Cheng,et al. Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models , 2006, Clinical Cancer Research.
[19] H. Hansen,et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.
[20] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[21] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[22] Wenyi Wei,et al. Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin* , 2002, The Journal of Biological Chemistry.
[23] Y. Pommier. Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.
[24] Y. Matsuzaki,et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. , 2002, Cancer research.
[25] F. Muggia,et al. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. , 1972, Cancer chemotherapy reports.
[26] Jianjun Cheng,et al. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. , 2003, Bioconjugate chemistry.
[27] A. Munkarah,et al. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. , 2002, The oncologist.
[28] Eng-Hui Chew,et al. Inhibition of Hypoxia-Inducible Factor-1α (HIF-1α) Protein Synthesis by DNA Damage Inducing Agents , 2010, PloS one.
[29] Y. Minagawa,et al. Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines , 1997, Japanese journal of cancer research : Gann.